Rufen Sie uns an: 555-555-5555
Team & Partners

Management and operation

Dr. Michael Jakusch, CEO

Responsibility: Michael focuses on overall project management, planning and execution of preclinical and tox studies and the clinical program. In addition he takes care of financial planning and controlling. 

Background: He pursued an MBA program specializing on finance at the Danube University Krems. Since then he has been working on life science start-up projects, including Advanced Pharma Products GmbH and the AWS-PreSeed funded project Exokal.

Education and expertise: After having studied organic chemistry at the University of Technology, Vienna, he worked as a postdoc at the Swiss Federal Institute of Technology (ETH) in Zurich and as staff scientist and project manager at the Austrian Research Centers in Seibersdorf (ARCS, now AIT). 

Dr. Bernhard Küenburg
Head of Business Development

Responsibility: Bernhard will focus on overall strategic planning, business development, investor acquisition and relation as well as the acquisition of strategic partners and cooperation. 

Background: Since 1999 he served in general management positions at CarboGen, Siegfried, onepharm R&D and Biomedica, thus extending his expertise to M&A activities, marketing and sales, general management, corporate legal situations, patent strategy etc. He has built an excellent network into the pharmaceutical and medical device industry and has good contacts into the private equity and venture capital world. 

Education and expertise: After his education and PhD in organic chemistry at the University of Technology in Vienna, he gained a lot of expertise in the pharmaceutical industry as a process chemist in scale up and production, design and construction of API plants.

Dr. Andreas Teuschl

Chief Scientific Officer 

Responsibility: Andreas is the main inventor of the proprietary medical silk technology of MorphoMed. He holds the position of CSO and contributes with his scientific knowledge and experience in the field of silk proteins and its use in tissue regeneration as well as his scientific network.

Background: In 2012 he joined the University of Applied Sciences Technikum Wien and is currently the head of the City of Vienna Competence Team “Tissue Engineering – Signal Tissue”. In 2015 he was invited to join Prof. Kaplan's lab at Tufts University in Boston for a 6-month research stay to pursue joint ideas on silk proteins for tissue engineering applications. Andreas Teuschl has published several scientific articles and written patents in the field of silk proteins.  

Education and expertise: After his education as a chemist at the University of Technology, Vienna, he finished his diploma thesis in 2008 and his PhD thesis in 2012, both in the field of structural proteins including collagen and silk protein at the Ludwig Boltzmann Institute for Clinical and Experimental Traumatology/AUVA Research Center.

Priv.-Doz. Dr. Thomas Nau

Chief Medical Officer

Responsibility: Thomas is the medical expert on all medical topics and questions. He contributes to designing and executing the clinical study, developing the medical positioning of the products and supporting the strategic pipeline planning.  

Background: Thomas is an experienced surgeon and specialist for knee injuries. He has implanted RegACLs in rabbit and sheep studies and was the first surgeon using RegACL prototypes. 

Habilitation: He finished his habilitation at the Medical University of Vienna in 2006 and holds a professorship at the AUVA Research Center for experimental and clinical traumatology. After positions in Australia, Tasmania and Austria he now acts as consultant orthopedic surgeon at the American Hospital in Dubai and is now Adjunct Professor of the Ludwig Boltzmann Institute for Experimental and Clinical Traumatology.

Education and first expertise: Thomas was educated at the Karl-Franzens University Graz and did his specialist training at the Medical University of Vienna. He has been a certified orthopedic trauma surgeon since 2003 with additional fellowship training in sports medicine and knee surgery. After fellowships at the University of Montreal, Canada, he completed his training at the University of Cape Town, South Africa, and at Monash University in Melbourne, Australia.

Dr. Udo Elsner 

Corporate Legal Affairs

Responsibility: Udo takes care of the development of the corporate structure, as well as of all sorts of contracts and legal issues. He also supports the team with the acquisition of investors and the negotiation of capital rounds.

Education and background: He is an experienced lawyer with over 25 years of experience and a strong background in corporate law but also in the legal support of life science companies including in the areas of license negotiations, M&A and settlements. He received his PhD in law from the University of Law, Vienna.

Dr. Michael Hammerschmid

Head QM and Manufacturing

Responsibility:Michael will be responsible for all topics regarding production and quality management. His longtime experience within the biopharmaceutical industry represents an optimal basis for these tasks. In addition he will support project management and strategic planning activities.

Background:  Michael is founder of Transform Science GmbH and has more than 17 years professional experience in the biopharmaceutical industry in different management positions.

Education:  Michael finished his education and holds a PhD in Food- and Biotechnology at the University of Natural Resources and Life Sciences, Vienna.

Scientific advisory board

Prof. Dr. Heinz Redl 

Head of scientific advisory board

Responsibility: Heinz leads the scientific advisory board, stays in touch with other advisors and gives strategic scientific input on present and future projects and technologies. 

Background: Heinz has been the managing director of the Ludwig Boltzmann Institute for Experimental and Clinical Traumatology in the AUVA Research Center since 1998 and founded the Austrian Cluster for Tissue Regeneration in 2006. 

Education and honors: Heinz habilitated at the University of Technology, Vienna, in chemical engineering. He has published and co-authored over 500 Pub Med cited publications and holds 10 patents. He is author of several books, editor in chief of Springer and member on numerous editorial boards. He has organized international conferences and is the Chair of  TERMIS-Europe.

Partners

Share by: